Department of Medical Physics, University of Wisconsin - Madison, Madison, WI.
Semin Radiat Oncol. 2023 Jul;33(3):317-326. doi: 10.1016/j.semradonc.2023.03.011.
Radiopharmaceutical therapy (RPT) is an invigorated form of cancer therapy that systemically delivers targeted radioactive drugs to cancer cells. Theranostics is a type of RPT that utilizes imaging, either of the RPT drug directly or a companion diagnostic, to inform whether a patient will benefit from the treatment. Given the ability to image the drug onboard theranostic treatments also lends itself readily to patient-specific dosimetry, which is a physics-based process that determines the overall absorbed dose burden to healthy organs and tissues and tumors in patients. While companion diagnostics identify who will benefit from RPT treatments, dosimetry determines how much activity these beneficiaries can receive to maximize therapeutic efficacy. Clinical data is starting to accrue suggesting tremendous benefits when dosimetry is performed for RPT patients. RPT dosimetry, which was once performed by florid and often inaccurate workflows, can now be performed more efficiently and accurately with FDA-cleared dosimetry software. Therefore, there is no better time for the field of oncology to adopt this form of personalize medicine to improve outcomes for cancer patients.
放射性药物治疗（RPT）是一种强化的癌症治疗形式，它将靶向放射性药物系统地输送到癌细胞中。放射性药物治疗是一种利用成像技术（直接对 RPT 药物进行成像或对伴随诊断进行成像）来告知患者是否会从治疗中受益的方法。鉴于能够对船上的治疗药物进行成像，放射性药物治疗还很容易进行患者特异性剂量测定，这是一种基于物理的过程，可确定健康器官和组织以及患者肿瘤的总吸收剂量负担。虽然伴随诊断可以确定谁将从 RPT 治疗中受益，但剂量测定决定了这些受益者可以接受多少活性物质，以最大限度地提高治疗效果。临床数据开始积累，表明当对 RPT 患者进行剂量测定时，会带来巨大的益处。RPT 剂量测定曾经是通过繁琐且常常不准确的工作流程进行的，但现在可以使用经过 FDA 批准的剂量测定软件更高效、更准确地进行。因此，现在是肿瘤学领域采用这种个性化医疗形式来改善癌症患者治疗效果的绝佳时机。
